Close Cookie Popup
Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

The NLC Health Impact Fund

Your access to the €10 trillion healthcare revolution

Submit your investment preferences to stay informed

Why invest in healthcare

A shortage of healthcare professionals and an aging population: healthcare is one of the biggest challenges of our time. Yet the toughest challenges can turn into the most rewarding investments.

Your safest gateway to unlock the potential of this €10 trillion market  is the NLC Health Impact Fund.

Why invest in the nlc health impact fund

Instead of investing in a single venture, you invest in the NLC Health Impact Fund, the newest flagship fund of the world's largest healthtech venture builder. You invest in a portfolio of 80-90 ventures from pre-seed to Series A/B and provides you access to healthcare innovations originating from world-renowned universities, hospitals and corporates, that are carefully vetted, supported and scaled by NLC.

the benefits of investing in our fund

High impact
00:00
/
00:00
High impact

As a certified B Corp, NLC supports UN Sustainable Development Goals and adheres to high impact standards (SDFR 9), making it an attractive option for investors seeking both financial returns and positive societal impact.

Derisking through diversification and scale
00:00
/
00:00
Derisking through diversification and scale

With a target size of €100 million, the fund aims to invest in 80-90 ventures and thus investors invest in a diverse portfolio of ventures. The ventures are based across Europe and the US, in the fields of medtech, biotech and digital health, and have different maturity levels. This strategy not only makes early-stage investments more attractive by reducing the risk associated with any single investment, but also enhances the potential for high returns by exposing investors to a broader range of innovative ventures.

Unrivalled healthcare expertise
00:00
/
00:00
Unrivalled healthcare expertise

Investing in The NLC Health Impact Fund means investing in the ventures of NLC Health Ventures. With more than 80 healthcare professionals, NLC has a proven track record of finding the most promising technologies, building and scaling over 120 ventures since inception, 22 of them in 2023 alone.

Live fund and optimal allocation
00:00
/
00:00
Live fund and optimal allocation

Since the first close of the fund in June 2023, the fund has already made its first 50 investments, giving investors joining in a new closing a tangible insight into a large part of the fund’s portfolio. Furthermore, the co-investment structure of the NLC Health Impact Fund ensures that the fund is able to ‘follow the winners’ as capital will be allocated to the most successful ventures in NLC’s portfolio.

the numbers

100M
Target fund size
80-90
Target nr. of portfolio companies
50
Investments made to date
10
Countries active in to date
SDFR 9
Compliant
80+
Healthcare experts in the team
"We invest in innovative companies that keep healthcare accessible and affordable. We see major challenges in healthcare, for which NLC can find suitable innovations from around the world and build them into companies. Our collaboration will make it possible to get these innovations to the patient faster."

VGZ

Dutch Healthcare Insurer

"We believe that investments that are both sustainable and impactful, produce positive results for society. By partnering with specialized funds like NLC, we can achieve financial returns while advancing promising innovations. "

Tessa van der Valk

Managing Director Mr. Roelsefonds

"High quality VC funds in healthcare are relatively rare in Europe, especially when combined with the expertise, depth and strength of the team. Moreover the quality of their process, combined with the venture builder and then providing access to the portfolio companies gives them an undeniable edge when it comes to both impact and return expectations."

Avalon Hill Management

Family Office

"I invested in NLC because it has built a disruptive platform for investment in the (pre)seed phase, generating both high societal impact and high return. For me it is an exciting novel asset category, I am pleased to be part of this journey."

Ivo Lurvink

Founder of True Value Partners and ex-partner at CVC Capital Partners.

Get in touch and explore the opportunities

A selection of ventures in
the NLC health impact fund

Mitracept
Transforming lives by unlocking hearts

Mitracept presents an innovative solution to address the challenges associated with LVOTO during TMVR. Through a groundbreaking, minimally invasive technology developed in partnership with the Mayo Clinic, the device helps reduce the risk of LVOTO during TMVR significantly. This approach provides a level of precision, control, and adaptability suitable for both non-calcified and calcified anatomies. By offering a simple and effective solution that fits in seamlessly with the procedural flow of TMVR, Mitracept reduces procedure time, complexity, and associated risks.

Active
🇺🇸 United States of America
Mitracept
Loresa
Improving access to laparoscopy in low-resource settings

Laparoscopic surgery, while effective, faces limitations in low-resource areas due to cost and sustainability concerns associated with CO2 insufflation. Gasless laparoscopy provides an alternative, that are costly and difficult to use. To address these challenges, LORESA has developed an affordable and user-friendly gasless laparoscopy retractor, designed with input from surgeons worldwide, offering improved usability and cost-effectiveness. This innovation, aims to democratize laparoscopic techniques, benefiting rural hospitals and developing communities.

Active
🇳🇱 Netherlands
Loresa
Foveo
Enhancing assisted fertility through optimal environment control

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

Active
🇬🇧 United Kingdom
Foveo
Nicolab
Image analysis for the improvement of stroke treatment

Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.

Active
🇳🇱 Netherlands
Nicolab
Xtrna Bio
Developing gene therapy to treat Charcot-Marie-Tooth disease

XtRNA Bio is developing a pioneering gene therapy to treat Charcot Marie Tooth (CMT) disease type 2D, leveraging tRNA supplementation therapies. Their patented treatment targets mutations in tRNA synthetases, offering a new therapeutic modality with vast potential for various diseases. They are raising €5M to develop a clinical candidate for CMT2D and expand their pipeline. CMT, a hereditary and heterogeneous disease, affects 1 in 2500 people worldwide, causing progressive muscle wasting, loss of sensation, and chronic pain, with no current cure.

Active
🇳🇱 Netherlands
Xtrna Bio
Scinvivo
Optical biopsy for bladder cancer diagnosis

Scinvivo introduces a solution for bladder cancer diagnosis with its imaging catheter, providing real-time, cross-sectional tissue images. Traditional methods often lead to unnecessary surgeries and missed tumors. By utilizing Optical Coherence Tomography technology, Scinvivo's catheter offers high-resolution imaging, enabling urologists to accurately diagnose bladder conditions. This approach reduces unnecessary surgeries but also enhances diagnostic accuracy, improving patient outcomes.

Active
🇳🇱 Netherlands
Scinvivo
Serda
Innovative enzymatic wound debrider offers fast, gentle healing solution

SERDA presents a solution for wound debridement, particularly useful for burn wounds and chronic wounds like diabetic foot ulcers. Traditional debridement methods can be expensive, painful, or less effective. SERDA offers an enzymatic debrider in the form of a hydrogel that selectively breaks down necrotic tissue, leaving healthy tissue intact, promoting faster healing with minimal discomfort for the patient. SERDA aims to improve the efficiency and ease of wound care, providing a more effective alternative to existing options.

Active
🇳🇱 Netherlands
Serda
Ecomedic
Enabling a 'net zero' emission in health sector

Ecomedic is dedicated to helping hospitals reduce their carbon footprint, addressing the healthcare sector's contribution to global emissions. Ecomedic's database and software tools enable environmental impact analyses, identify sources of emissions and measures the effect of alternative solutions. By providing insights and solutions, the institutions are supported in achieving their carbon neutrality goals and reducing operational costs.

Active
🇬🇧 United Kingdom
Ecomedic

Key considerations

As with all investments carrying risk, the value of your investment in NLC and its Health Impact Fund could be lost, in full or in part due to unexpected developments. Some of the key risks are listed below. Prospective investors are advised to consult the Information Memorandum of this Fund.

Restricted tradeability

As a closed-end fund, the interests are not freely tradeable. If an investor wishes to sell their fund holdings before the end of the 10-year term, their obtained returns might be negatively affected or the interests might not be tradable or will only be tradable to a limited extent because of lack of another person acquiring their interests. Investors could, thus, be bound to this investment longer than expected or desired.

Start-up risk

The Fund invests in healthtech startups, which are inherently of high risk. Several of the portfolio companies in which the Fund will invest will not be able to turn their current projects into fully commercialized products certified for medical use, negatively affecting the value of the investment.

Market risk

Many of the portfolio companies are projected to need one or more follow-on financing rounds to successfully launch their product on the market. While the fund itself can, inmost instances, also provide this follow-on financing, such investments always need to be matched by external investors. If the portfolio companies are unable to secure this funding, it might lead to a delay or a lack of sources to continue the developmental trajectories of one or more portfolio companies.

Insights

Create a healthier future with us

Hidde ten Brink
Investment Director
Nina Rijnders
Investor Relations
Disclaimer
The Health Impact Fund is accessible to investors residing in all the EU Member States. Investors acquire interests in the Health Impact Fund and not direct ownership in any underlying asset in which the Fund invests. No leverage is used at the fund level.

This webpage is a marketing material which has been prepared by NLC Fund Management B.V. (‘NLC’) with the purpose of sharing relevant information concerning the funds under their management. It does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, which will only be made by means of an information memorandum and/or subscription documents. You may not rely on this webpage as the basis upon which to make an investment decision. This webpage does not purport to be complete on any topic addressed. NLC has not verified or analyzed the information included in this webpage for accuracy or completeness. NLC shall not bear any liability for the information contained in, or any omissions from, this webpage.